A61P 21 - Drugs for disorders of the muscular or neuromuscular system

Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
10/2002
10/31/2002	US20020160984 For example, 2,3-dihydro-1H-benz(de)isoquinolin-1-one; treating diabetes, cancer, radiosensitizing tumor cells, cardiovascular disorders, septic shock, inflammatory bowel disease, senescent cells
10/31/2002	US20020160974 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/31/2002	US20020160940 Modulation of endogenous gene expression in cells
10/31/2002	US20020160059 Treatment of urogenital disorders, menstrual cramps
10/31/2002	US20020160000 PD-1, a receptor for B7-4, and uses therefor
10/31/2002	US20020159956 Providing a chewing gum, includes a gum center and a coating coverings, coating includes a drug designed to be delivered into systemic system of indivisual
10/31/2002	DE10121217A1 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden 6H-oxazolo [4,5-e] indole derivatives as nicotinic acetylcholine receptor ligands and / or serotonergic ligands
10/31/2002	DE10121215A1 Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden Dihydro-imidazo [4,5-e] indole and 7H-pyrrolo [3,2-f] quinoxaline derivatives as nicotinic acetylcholine receptor ligands and / or serotonergic ligands
10/31/2002	CA2843001A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
10/31/2002	CA2445255A1 Vhh single heavy chain antibody and a method for its preparation in a mammal
10/31/2002	CA2444959A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
10/31/2002	CA2444675A1 Secreted proteins
10/31/2002	CA2444599A1 Melanocortin receptor ligands
10/31/2002	CA2443600A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002	CA2442112A1 Use of creatine for the amelioration of oxidative stress
10/30/2002	EP1252333A2 Methods and materials relating to cd84-like polypeptides and polynucleotides
10/30/2002	EP1252158A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
10/30/2002	EP1252157A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
10/30/2002	EP1252150A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
10/30/2002	EP1251855A1 Selective estrogen receptor modulators in combination with estrogens
10/30/2002	EP1251853A1 Transdermal therapeutic system for the administration of zaleplon
10/30/2002	EP1251842A2 Use of modafinil for making a medicine for correcting disorders affecting vigilance related to myopathies
10/30/2002	EP1251829A1 Electrospun pharmaceutical compositions
10/30/2002	CN1377424A Methods of reparing tandemly repeated DNA sequences and extending cell life-span using nuclear transfer
10/30/2002	CN1377368A 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
10/30/2002	CN1377367A Sapogenin derivatives and their use in the treatment of cognitive dysfunction
10/30/2002	CN1377366A 5-hydroxysapogenin derivatives with anti-dementia activity
10/30/2002	CN1377352A Selective antagonists of A28 adenosine receptors
10/30/2002	CN1377259A ACE-2 inhibiting compounds and methods of use thereof
10/30/2002	CA2383469A1 Treatment of t-cell mediated diseases
10/29/2002	US6472434 Vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives,
10/29/2002	US6472390 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
10/29/2002	US6472378 Compositions and methods for treatment of mitochondrial diseases
10/24/2002	WO2002083926A2 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	WO2002083873A2 Enzymes
10/24/2002	WO2002083716A2 Type b botulism toxin inhibitors
10/24/2002	WO2002083712A2 Transporters and ion channels
10/24/2002	WO2002083709A2 Kinases and phosphatases
10/24/2002	WO2002083668A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	WO2002083667A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	WO2002083664A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083663A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083648A1 Novel 1h-indazole compound
10/24/2002	WO2002083642A1 Compounds useful as anti-inflammatory agents
10/24/2002	WO2002083628A1 1,4-disubstituted benzo-fused compounds
10/24/2002	WO2002083186A1 Nuclear receptor-mediated introduction of a pna into cell nuclei
10/24/2002	WO2002083158A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles
10/24/2002	WO2002083122A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	WO2002083115A1 Treatment of disorders secondary to organic impairments
10/24/2002	WO2002083106A1 Controlled delivery of tetracycline compounds and tetracycline derivatives
10/24/2002	WO2002057253A3 Isoindolyl and isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002050057A8 Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2001074848A3 Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	US20020156102 Piperidine amides as modulators of chemo kine receptor activity
10/24/2002	US20020156101 Use for pain management
10/24/2002	US20020156050 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors
10/24/2002	US20020156024 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
10/24/2002	US20020156001 Novel fibroblast growth factor ( FGF23) and methods for use
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155539 Calcium channel polynucleotides, polypeptides, and antibodies
10/24/2002	US20020155098 Methods for treating the inflammatory component of a brain disorder
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	CA2490819A1 Compounds useful as anti-inflammatory agents
10/24/2002	CA2447008A1 Controlled delivery of tetracycline compounds and tetracycline derivatives
10/24/2002	CA2444548A1 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	CA2443897A1 Transporters and ion channels
10/24/2002	CA2443811A1 Type b botulism toxin inhibitors
10/24/2002	CA2443697A1 1,4-disubstituted benzo-fused compounds
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2442953A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	CA2440842A1 Novel 1h-indazole compounds
10/23/2002	EP1251131A2 Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases
10/23/2002	EP1251128A1 Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists
10/23/2002	EP1250849A1 Morinda citrifolia (Noni) enhanced animal food product
10/23/2002	EP1250357A1 Myostatin and mimetics thereof
10/23/2002	EP1250338A1 Pyrazino-pyridazine derivatives as ligands for gaba receptors
10/23/2002	EP1250156A1 Method for nucleic acid transfection of cells
10/23/2002	EP0767170B1 Novel 4,6-diarylpyrimidine derivatives and salts thereof
10/23/2002	CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002	CN1092971C Chinese medicine for treating rheumatism
10/22/2002	US6469174 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
10/22/2002	US6469054 Aryl sulphonamides and analogues
10/22/2002	US6469024 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
10/22/2002	US6469019 Prevention/treatment of motor neuron diseases; amyotrophic lateral sclerosis
10/22/2002	US6469018 Compounds
10/22/2002	US6469016 Treatment of female sexual dysfunction using phosphodiesterase inhibitors
10/22/2002	US6468978 Conjugate comprising 1 to 4 moieties covalently bound to polypeptide comprising hedgehog n-terminal domain, each being polypeptide containing 10 to 30 hydrophobic amino acids or positively charged amino acids forming transmembrane helices
10/22/2002	US6468794 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
10/17/2002	WO2002081684A2 Antisense calpain nucleotides and uses thereof
10/17/2002	WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002	WO2002081398A2 Additives for building industry obtained from by-products and process for their production
10/17/2002	WO2002080976A2 Hsa-free formulations of interferon-beta
10/17/2002	WO2002080966A2 Method for producing a vaccine containing autologous antibodies
10/17/2002	WO2002080945A2 Methods for treating the inflammatory component of a brain disorder

1 ... 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 ... 233